BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the ...
Current status of phase III anti-EGF-receptor antibody (OSAG-101) for newly diagnosed glioblastoma. Background: There is currently no standardized therapy for high-grade gliomas after recurrence.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback